RnRMarketResearch.

com adds report EpiCast Report: Dyslipidemia Epidemiology Forecast to 2023

to its store.

Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-
established risk factor for cardiovascular disease, and the burden of morbidity, mortality, and medical
costs arising from dyslipidemia is substantial.

GlobalData epidemiologists forecast that the total prevalent cases of dyslipidemia in the 8MM will
increase from 572,418,492 total prevalent cases in 2013, to 685,905,635 total prevalent cases in 2023,
at an Annual Growth Rate (AGR) of 1.99%. All markets will see an increase in the total prevalent cases of
dyslipidemia at varying AGRs, except for Germany, which will see a decrease. The 8MM had an
estimated 3,339,447 total prevalent cases of FH in 2013, and the number of total prevalent cases of FH
is expected to increase to 4,365,831 by 2023, at an AGR of 3.07%. All markets will see an increase in the
total prevalent cases of FH at varying AGRs, except for Japan, which will see a decrease. Additionally,
GlobalData epidemiologists forecast that the total prevalent cases of increased LDLc in the 8MM will
increase from 345,008,543 total prevalent cases in 2013 to 411,737,455 total prevalent cases in 2023, at
an AGR of 1.93%. All markets will see an increase in the total prevalent cases of increased LDLc at
varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 10,777,756
total prevalent cases of very high TG (=500mg/dL) in 2013, and the number of total prevalent cases of
very high TG is expected to increase to 12,746,492 by 2023, at an AGR of 1.83%. All markets will see an
increase in the total prevalent cases of very high TG at varying AGRs, except for Germany and Japan,
which will see a decrease.

Complete report available @ http://www.rnrmarketresearch.com/epicast-report-dyslipidemia-
epidemiology-forecast-to-2023-market-report.html .

GlobalData epidemiologists used comprehensive, country-specific data from population based national
health surveys such as NHANES in the US, the HSE in the UK, and the CHNS in urban China, in addition to
data from peer-reviewed journal articles, to arrive at a meaningful, in-depth analysis and forecast for
the total prevalent cases of dyslipidemia, and other therapeutically significant patient populations
including the total prevalent cases of increased LDLc and very high TG (=500mg/dL). For all the 8MM,
the total prevalent cases of dyslipidemia, increased LDLc, and very high TG (=500mg/dL) were
segmented by age and sex, which facilitates an understanding of the distribution of disease within the
population, and informs strategies to improve the management of disease.

Scope

The Dyslipidemia EpiCast Report provides an overview of the risk factors, comorbidities, and the
global and historical epidemiological trends for dyslipidemia in the eight major markets (8MM) (US,
France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological
forecast for the total prevalent cases of dyslipidemia (defined as: increased low-density lipoprotein
cholesterol [LDLc], high triglycerides [TG] [=200mg/dL], or low levels of high-density lipoprotein
cholesterol [HDLc]), as well as the total prevalent cases of increased LDLc (=115mg/dL to =160mg/dL
based on country-specific cut-offs), and very high TG (=500mg/dL), segmented by sex and age (in 10-
year intervals beginning at 20 years and ending at =70 years). Additionally, the forecast provides the
total prevalent cases of familial hypercholesterolemia (FH) in these markets.
The dyslipidemia epidemiology report is written and developed by Mastersand PhD-level
epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert
analysis of disease trends in the 8MM.

Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=232644 .
(This is a premium report priced at US$2000 for a single user PDF.)

Reasons to buy

Develop business strategies by understanding the trends shaping and driving the global
dyslipidemia market.
Quantify patient populations in the global dyslipidemia market to improve product design,
pricing, and launch plans.
Organize sales and marketing efforts by identifying the sex and age groups that present the best
opportunities for dyslipidemia therapeutics in each of the markets covered.

List of Tables

Table 1: Risk Factors and Comorbidities for Dyslipidemia 15
Table 2: Overview of the Total Prevalence of Low HDLc in the 5EU 18
Table 3: NCEP-ATP III Classification of LDLc, TG, and HDLc 20
Table 4: Simon Broome Diagnostic Criteria for FH 21
Table 5: LDLc Based Definition of FH 21
Table 6: Sources of Total Prevalence Data for FH in the 8MM 22
Table 7: Sources of Total Prevalence Data for Increased LDLc in the 8MM 23
Table 8: Sources of Total Prevalence Data for High TG (?200mg/dL) in the 8MM 24
Table 9: Sources of Total Prevalence Data for Very High TG (?500mg/dL) in the 8MM 25
Table 10: Sources of Total Prevalence Data for Low HDLc in the 8MM 26
Table 11: 8MM, Sources Not Used in the Epidemiological Analysis of Dyslipidemia 34
Table 12: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013-2023 61
Table 13: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, N (Row %), 2013 62
Table 14: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, N (Row %), 2013 64
Table 15: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ?20 Years, N,
2013-2023 66
Table 16: 8MM, Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Both Sexes, Ages
?20 Years, N, 2013-2023 68
Table 17: 8MM, Age-Specific Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Both
Sexes, N (Row %), 2013 70
Table 18: 8MM, Sex-Specific Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Ages
?20 Years, N (Row %), 2013 72
Table 19: 8MM, Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N,
2013-2023 75
Table 20: 8MM, Age-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, N (Row %),
2013 76
Table 21: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Ages ?20 Years, N (Row
%), 2013 78

Purchase a copy of this report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=232644 .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes
450,000+ market research reports from over 95 leading global publishers & in-depth market research
studies of over 5000 micro markets. We offer you customization options on reports by & custom reports
through MarketsandMarkets.com. With comprehensive information about the publishers and the
industries for which they publish market research reports, we help you in your purchase decision by
mapping your information needs with our huge collection of reports.